Page last updated: 2024-11-12

lc15-0444

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LC15-0444: Dipeptidyl Peptidase IV Inhibitors; orally active small molecule for the treatment of type II diabetes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11953153
CHEMBL ID3707235
CHEBI ID134731
SCHEMBL ID1262740
MeSH IDM0529203

Synonyms (33)

Synonym
CHEBI:134731
gemigliptin
lc15-0444
pyrido(3,4-d)pyrimidine, 7-((3s)-3-amino-4-(5,5-difluoro-2-oxo-1-piperidinyl)-1-oxobutyl)-5,6,7,8-tetrahydro-2,4-bis(trifluoromethyl)-
2-piperidinone, 1-((2s)-2-amino-4-(5,8-dihydro-2,4-bis(trifluoromethyl)pyrido(3,4-d)pyrimidin-7(6h)-yl)-4-oxobutyl)-5,5-difluoro-
gemigliptin [inn]
5dhu18m5d6 ,
911637-19-9
1-((2s)-2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4-d)pyrimidin-7(6h)-yl)-4-oxobutyl-5,5-difluoropiperidin-2-one
unii-5dhu18m5d6
D10502
gemigliptin (prop.inn)
gemigliptin [who-dd]
1-((2s)-2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4-d)pyrimidin-7(6h)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one
lc-150444
lc-15-0444
CHEMBL3707235
SCHEMBL1262740
AKOS025290873
(s)-1-(2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6h)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one
(s)-1-(2-amino-4-(2,4-bis(trifluoromethyl)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8h)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one ,
DB12412
A854536
Q5530612
CS-0003618
HY-14892
1-[(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one
911637-19-9 (free base)
gemigliptin hydrochloride
AS-75936
DTXSID501030150
zwprrqznbdyklh-vifpvbqesa-n
1-[(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxo-butyl]-5,5-difluoro-piperidin-2-one

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The incidences of adverse events were similar in all study subjects."( A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Bae, HY; Baik, SH; Cha, BS; Kim, DK; Kim, JA; Kim, MJ; Kim, SW; Kim, YK; Lee, HW; Lee, IK; Lee, MK; Lee, WY; Min, KW; Park, JY; Park, KS; Rhee, EJ; Yoo, SJ; Yoon, KH, 2010
)
0.36
" The overall incidence rates for adverse events were similar in the gemigliptin and placebo groups."( A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
Agarwal, PK; Baik, SH; Dharmalingam, M; Gandhi, P; Gupta, SK; Kim, DM; Kim, JA; Kim, PK; Kim, YS; Mahesh, U; Min, KW; Mohan, V; Park, JY; Pitale, SU; Shivane, VK; Sosale, A; Yang, SJ, 2013
)
0.59
" There was no increased risk of adverse effects with this dose of gemigliptin compared with sitagliptin 100 mg qd."( Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Chung, CH; Jang, HC; Kim, JA; Kim, SW; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR, 2013
)
0.39
"This review considers the pharmacokinetic profile, adverse effects and drug interactions of DPP-4 inhibitors."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
" However, DPP-4 inhibitors have certain differences in their pharmacokinetic properties that may be associated with different clinical effects and adverse event profiles."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
" The overall rates of adverse events were similar between the 2 groups."( Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Cha, DR; Han, BG; Han, SY; Jang, Y; Jeong, KH; Jo, YI; Kang, SW; Kim, B; Kim, NH; Kim, SG; Na, KR; Oh, KH; Park, HC; Park, SH; Shin, S; Yoon, SA, 2018
)
0.48
" There were no significant differences in adverse events among the groups."( Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial.
Bae, JC; Cha, BS; Han, S; Hong, EG; Kim, KA; Kim, YH; Min, KW; Park, CY, 2019
)
0.51
"The FDC of gemigliptin and rosuvastatin is safe and is effective in reducing both blood glucose and LDL-C levels; thus, it could be a good therapeutic choice for type 2 diabetic patients with dyslipidaemia."( Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial.
Bae, JC; Cha, BS; Han, S; Hong, EG; Kim, KA; Kim, YH; Min, KW; Park, CY, 2019
)
0.51
" The incidence of overall adverse events and the number of hypoglycaemic adverse events were similar between the study groups."( Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).
Benjachareonwong, S; Chamnan, P; Cho, YM; Choi, S; Deerochanawong, C; Kang, ES; Kim, S; Kosachunhanun, N; Kwon, S; Lee, MK; Lee, WJ; Oh, T; Pratipanawatr, T; Sattanon, S; Seekaew, S; Sirirak, T; Suraamornkul, S; Suwanwalaikorn, S, 2020
)
0.56
" The secondary outcomes were alterations in glucose, glycaemic targets, lipids, insulin resistance, and adverse events."( Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis.
Agarwal, A; Dutta, D; Khandelwal, D; Maisnam, I; Sharma, M; Singla, R, 2021
)
0.62
" The incidence of treatment-emergent adverse events was similar between the groups (21."( Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study.
Cho, JH; Han, JM; Han, JY; Han, KA; Kang, ES; Kang, JG; Kim, CS; Kim, KS; Kim, MK; Kim, NH; Kim, S; Kim, SH; Kim, SS; Kim, SY; Kim, TH; Kim, TN; Kim, YH; Koh, G; Lee, JH; Lee, KY; Lee, SE; Lim, S; Mok, JO; Nah, JJ; Park, CY; Park, JH; Song, HR; Song, KH; Won, KC, 2023
)
0.91

Pharmacokinetics

LC15-0444 possesses pharmacokinetic and pharmacodynamic characteristics that support a once-daily dosing regimen. The aim of this study was to investigate the pharmacokinetics (PK), pharmacodynamic (PD), and tolerability profiles of a single dose of LC15- 0444 in healthy male subjects.

ExcerptReferenceRelevance
"The aim of this study was to investigate the pharmacokinetic (PK), pharmacodynamic (PD), and tolerability profiles of a single dose of LC15-0444 in healthy male subjects."( Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Cho, JY; Choi, YJ; Hong, JH; Hwang, DM; Jang, IJ; Kim, JA; Kim, JR; Kim, KP; Kwon, OH; Lim, KS; Shin, HS; Shin, KH; Shin, SG; Yu, KS, 2008
)
0.77
" * LC15-0444 possesses pharmacokinetic and pharmacodynamic characteristics that support a once-daily dosing regimen."( Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
Cho, JY; Jang, IJ; Kim, BH; Kim, DK; Kim, HS; Kim, JR; Kim, SH; Lee, SH; Lim, KS; Shin, SG; Yim, HJ; Yu, KS, 2009
)
1.24
" The aim was to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) profiles after multiple oral ascending doses of LC15-0444 in healthy male subjects."( Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
Cho, JY; Jang, IJ; Kim, BH; Kim, DK; Kim, HS; Kim, JR; Kim, SH; Lee, SH; Lim, KS; Shin, SG; Yim, HJ; Yu, KS, 2009
)
0.82
" Mean elimination half-life was in a range 16."( Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
Cho, JY; Jang, IJ; Kim, BH; Kim, DK; Kim, HS; Kim, JR; Kim, SH; Lee, SH; Lim, KS; Shin, SG; Yim, HJ; Yu, KS, 2009
)
0.62
"The effects of multiple oral doses of ketoconazole (a potent CYP3A4 inhibitor) and multiple oral doses of rifampicin (a potent CYP3A4 inducer) on the pharmacokinetic properties of a single oral dose of gemigliptin were evaluated in fasting healthy male Korean volunteers."( Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Bae, KS; Choi, HY; Jin, SJ; Kim, MJ; Kim, YH; Lim, HS; Noh, YH; Sung, HR, 2012
)
0.38
" Pharmacokinetic parameters were estimated via noncompartmental methods."( Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Bae, KS; Choi, HY; Jin, SJ; Kim, MJ; Kim, YH; Lim, HS; Noh, YH; Sung, HR, 2012
)
0.38
" This study was conducted to investigate the effects of food on the pharmacokinetic (PK) profile of the FDC tablets."( Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
Bae, KS; Choi, HY; Kim, B; Kim, JA; Kim, MJ; Kim, YH; Lee, SH; Lim, HS; Noh, YH, 2014
)
0.4
" This study evaluated possible pharmacodynamic and pharmacokinetic interactions between gemigliptin and metformin and investigated their tolerability."( Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Ahn, JY; Cho, JY; Cho, YM; Jang, IJ; Kim, JA; Lee, H; Lee, S; Lim, KS; Shin, D; Yu, KS, 2014
)
0.4
" Blood samples were drawn over 24 h on the seventh day of each period for pharmacokinetic and pharmacodynamic evaluations, including plasma DPP-4 activity and total/active glucagon-like peptide-1 (GLP-1) levels."( Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Ahn, JY; Cho, JY; Cho, YM; Jang, IJ; Kim, JA; Lee, H; Lee, S; Lim, KS; Shin, D; Yu, KS, 2014
)
0.4
"Coadministration of gemigliptin and metformin showed beneficial anti-diabetic effects without pharmacokinetic drug-drug interactions."( Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Ahn, JY; Cho, JY; Cho, YM; Jang, IJ; Kim, JA; Lee, H; Lee, S; Lim, KS; Shin, D; Yu, KS, 2014
)
0.4
"21-fold) increase of mean area under the time-plasma concentration curve from 0 to infinity (AUCinf) [maximum plasma concentration (Cmax)] of gemigliptin, respectively."( Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444).
Kim, EY; Kim, N; Kim, YH; Lee, SH; Oh, MK; Park, SJ; Shin, JG; Shon, JH, 2014
)
0.63
"This review considers the pharmacokinetic profile, adverse effects and drug interactions of DPP-4 inhibitors."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
" However, DPP-4 inhibitors have certain differences in their pharmacokinetic properties that may be associated with different clinical effects and adverse event profiles."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
"Gemigliptin and glimepiride did not alter the pharmacokinetic properties of each other when they were co-administered in healthy volunteers, and were generally tolerated."( Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Bae, KS; Bang, K; Choi, HY; Han, S; Kim, MJ; Kim, YH; Lee, SH; Lim, HS, 2014
)
0.4
"The primary PK parameters - Cmax and AUCτ - were compared to the geometric mean ratios (GMRs) and 90% confidence intervals (90% CIs) that were determined for the combination therapies and monotherapies."( Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Bae, KS; Choi, HY; Jeon, HS; Jung, JH; Kim, HJ; Kim, MJ; Kim, YH; Lee, SH; Lee, YK; Lim, HS, 2015
)
0.42
" The objective of the study reported here was to compare the pharmacodynamic (PD), pharmacokinetic (PK), and tolerability profiles of gemigliptin and extended-release metformin (metformin XR) between FDC and separate tablets."( A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Jang, IJ; Jung, JH; Kim, JA; Lee, H; Lim, KS; Oh, J; Park, SI; Yu, KS, 2015
)
0.42
"The aim of this study was to assess the pharmacokinetic interactions between a newly developed dipeptidyl peptidase (DPP)-4 inhibitor, gemigliptin, and metformin in healthy Mexican male volunteers, and the differences in the pharmacokinetic profile of gemigliptin between Korean and Mexican healthy volunteers."( Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
Conde-Carmona, I; García-Medina, S; Jiménez-Vargas, JM; Lee, SH; Martínez-Muñoz, A, 2018
)
0.48
" Subjects were randomized to 1 of 3 treatment sequences and received gemigliptin 50mg once a day, metformin1000mg BID, or both drugs during a 7-day treatment period, and underwent sampling for pharmacokinetic analysis and tolerability assessments."( Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
Conde-Carmona, I; García-Medina, S; Jiménez-Vargas, JM; Lee, SH; Martínez-Muñoz, A, 2018
)
0.48
" Considering the flat effect-concentration curve and wide therapeutic range of gemigliptin, the pharmacokinetic profile of gemigliptin observed in healthy Mexican and Korean subjects suggests that gemigliptin use in Mexican patients may be associated with outcomes, in terms of efficacy and tolerability, similar to those observed in the Korean population."( Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
Conde-Carmona, I; García-Medina, S; Jiménez-Vargas, JM; Lee, SH; Martínez-Muñoz, A, 2018
)
0.48
" The aim of this study was to assess the pharmacokinetic equivalence of the high dose of the FDC tablet (gemigliptin/metformin sustained release [SR] 50/1,000 mg) and a corresponding co-administered dose of individual tablets."( Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
Bae, KS; Cho, YS; Lee, SH; Lim, HS, 2018
)
0.48
"FDC tablet exhibited pharmacokinetic equivalence and comparable safety and tolerability to co-administration of corresponding doses of gemigliptin and metformin XR as individual tablets."( Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
Bae, KS; Cho, YS; Lee, SH; Lim, HS, 2018
)
0.48
" Pharmacokinetic parameters were derived using a noncompartmental method."( Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.
Chung, JY; Lee, S; Lee, SW; Park, SI; Yu, KS, 2019
)
0.51
" The PK and pharmacodynamic parameters were analysed by the noncompartmental method."( Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.
Huh, W; Hwang, JG; Jang, IJ; Jeong, SI; Kim, Y; Lee, S; Nah, JJ, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"In this open-label, 2-part, 3-treatment, 1-sequence, 2-period crossover drug-drug interaction study, 1 group of subjects received a single 50-mg oral dose of gemigliptin on 2 separate occasions-once as monotherapy and again after pretreatment with 400 mg of oral ketoconazole once daily for 7 days."( Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Bae, KS; Choi, HY; Jin, SJ; Kim, MJ; Kim, YH; Lim, HS; Noh, YH; Sung, HR, 2012
)
0.38
" These findings suggest that gemigliptin may require a dose adjustment when concurrently administered with drugs that alter CYP3A4 activity."( Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Bae, KS; Choi, HY; Jin, SJ; Kim, MJ; Kim, YH; Lim, HS; Noh, YH; Sung, HR, 2012
)
0.38
" Sulfonylureas are commonly used in combination with other antidiabetic drugs to improve glycemic control."( Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Bae, KS; Bang, K; Choi, HY; Han, S; Kim, MJ; Kim, YH; Lee, SH; Lim, HS, 2014
)
0.4
"The effect of the dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with the heat shock protein 90 inhibitor NVP-AUY922 (AUY922) on survival of thyroid carcinoma cells was elucidated."( The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.
Choi, MG; Ihm, SH; Kang, JG; Kim, CS; Kim, SH; Lee, SJ; Yoo, HJ, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" The (14)C-labeled gemigliptin was rapidly absorbed after oral administration, and its bioavailability was 95."( Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats.
Kim, DH; Kim, IS; Kim, U; Kim, Y; Lee, J; Lee, SH; Yoo, HH, 2014
)
0.4

Dosage Studied

LC15-0444 possesses pharmacokinetic and pharmacodynamic characteristics that support a once-daily dosing regimen. Doses >or=200 mg inhibited plasma DPP IV activity by >80% over a 24-hour dosing interval. A 600-mg dose increased active glucagon-like peptide-1 levels after a standardized meal.

ExcerptRelevanceReference
" In addition, doses >or=200 mg of LC15-0444 inhibited plasma DPP IV activity by >80% over a 24-hour dosing interval, and a 600-mg dose increased active glucagon-like peptide-1 levels after a standardized meal."( Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Cho, JY; Choi, YJ; Hong, JH; Hwang, DM; Jang, IJ; Kim, JA; Kim, JR; Kim, KP; Kwon, OH; Lim, KS; Shin, HS; Shin, KH; Shin, SG; Yu, KS, 2008
)
0.84
" * LC15-0444 possesses pharmacokinetic and pharmacodynamic characteristics that support a once-daily dosing regimen."( Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
Cho, JY; Jang, IJ; Kim, BH; Kim, DK; Kim, HS; Kim, JR; Kim, SH; Lee, SH; Lim, KS; Shin, SG; Yim, HJ; Yu, KS, 2009
)
1.24
" Blood and urine samples were collected up to 24 h after the first dosing and up to 72 h after the last dosing."( Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
Cho, JY; Jang, IJ; Kim, BH; Kim, DK; Kim, HS; Kim, JR; Kim, SH; Lee, SH; Lim, KS; Shin, SG; Yim, HJ; Yu, KS, 2009
)
0.62
" LC15-0444 possesses PK and PD characteristics that support a once-daily dosing regimen."( Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
Cho, JY; Jang, IJ; Kim, BH; Kim, DK; Kim, HS; Kim, JR; Kim, SH; Lee, SH; Lim, KS; Shin, SG; Yim, HJ; Yu, KS, 2009
)
1.53
" No dosage of LC15-0444 affected weight or waist circumference."( A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Bae, HY; Baik, SH; Cha, BS; Kim, DK; Kim, JA; Kim, MJ; Kim, SW; Kim, YK; Lee, HW; Lee, IK; Lee, MK; Lee, WY; Min, KW; Park, JY; Park, KS; Rhee, EJ; Yoo, SJ; Yoon, KH, 2010
)
0.72
" Clinical pharmacokinetic and pharmacodynamic data suggest the efficacy and once daily dosing of gemigliptin."( Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
Kim, SH; Lee, SH; Yim, HJ, 2013
)
0.39
" These results indicate that the FDC tablet can be administered in the same dosing regimen as each component, especially that of metformin sustained-release."( Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
Bae, KS; Choi, HY; Kim, B; Kim, JA; Kim, MJ; Kim, YH; Lee, SH; Lim, HS; Noh, YH, 2014
)
0.4
" Twenty-seven subjects received gemigliptin (50 mg once daily), metformin (1,000 mg twice a day), or both drugs for 7 days per dosing period."( Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Ahn, JY; Cho, JY; Cho, YM; Jang, IJ; Kim, JA; Lee, H; Lee, S; Lim, KS; Shin, D; Yu, KS, 2014
)
0.4
" Each subject received the following treatments (A and B) with a 7-day washout period: treatment A consisted of gemigliptin 50 mg once daily administered orally for 6 days, followed by concomitant oral dosing of glimepiride 4 mg and gemigliptin 50 mg on day 7; treatment B consisted of a single dose of glimepiride 4 mg."( Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Bae, KS; Bang, K; Choi, HY; Han, S; Kim, MJ; Kim, YH; Lee, SH; Lim, HS, 2014
)
0.4
" Each drug was administered as part of once daily, 7 day, repeated dosing regimens with a 14 day washout period."( Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Bae, KS; Choi, HY; Jeon, HS; Jung, JH; Kim, HJ; Kim, MJ; Kim, YH; Lee, SH; Lee, YK; Lim, HS, 2015
)
0.42
"Gemigliptin is a potent, selective dipeptidyl peptidase (DPP)-4 inhibitor that does not require any dosage adjustment based on renal function."( Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus.
Bae, J; Cha, BS; Cho, Y; Huh, KH; Joo, DJ; Kang, ES; Kim, MS; Kim, Y; Kim, YS; Lee, BW; Lee, JY; Lee, M; Lee, YH, 2019
)
0.51
" Safety was evaluated by examining its influence on immunosuppressive treatment, as determined by the blood trough level and dosage of calcineurin inhibitors, as well as changes in parameters related to liver and renal function."( Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus.
Bae, J; Cha, BS; Cho, Y; Huh, KH; Joo, DJ; Kang, ES; Kim, MS; Kim, Y; Kim, YS; Lee, BW; Lee, JY; Lee, M; Lee, YH, 2019
)
0.51
" The dosage of immunosuppressants was also stable."( Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus.
Bae, J; Cha, BS; Cho, Y; Huh, KH; Joo, DJ; Kang, ES; Kim, MS; Kim, Y; Kim, YS; Lee, BW; Lee, JY; Lee, M; Lee, YH, 2019
)
0.51
" Serial blood samples were collected up to 72 hrs after dosing to measure plasma concentrations of gemigliptin, its active metabolite LC15-0636, and rosuvastatin for PK assessment, and DPP-4 activity for PD assessment."( A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects.
Jang, IJ; Kim, E; Lee, S; Park, KR; Yu, KS, 2019
)
0.51
" For PK and PD analyses, serial blood samples were collected up to 72 hours after dosing to determine plasma concentrations of gemigliptin, its active metabolite LC15-0636 and rosuvastatin, and plasma dipeptidyl peptidase-4 (DPP-4) activity."( Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study.
Jang, IJ; Lee, S; Yang, E; Yoo, H; Yu, KS, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organonitrogen compoundAny heteroorganic entity containing at least one carbon-nitrogen bond.
organooxygen compoundAn organochalcogen compound containing at least one carbon-oxygen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (70)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (2.86)29.6817
2010's49 (70.00)24.3611
2020's19 (27.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.67 (24.57)
Research Supply Index4.68 (2.92)
Research Growth Index6.17 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials37 (52.86%)5.53%
Reviews3 (4.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (1.43%)0.25%
Other29 (41.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]